Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort

被引:7
|
作者
Lammi, Matthew R. [1 ]
Saketkoo, Lesley A. [2 ]
Gordon, Jessica K. [3 ]
Lauto, Paula [1 ]
Fagan, Karen [4 ]
Steen, Virginia D. [5 ]
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Pulm Crit Care & Allergy Immunol, New Orleans, LA USA
[2] Tulane Univ, Sch Med, Sect Pulm Dis Crit Care & Environm Med, 1430 Tulane Ave, New Orleans, LA 70112 USA
[3] Hosp Special Surg, Dept Rheumatol, 535 E 70th St, New York, NY 10021 USA
[4] Univ S Alabama, Pulm & Crit Care, Mobile, AL USA
[5] Georgetown Univ, Div Rheumatol, Washington, DC USA
基金
美国国家卫生研究院;
关键词
diastolic dysfunction; pulmonary hypertension; scleroderma; systemic sclerosis; treatment; 6-MINUTE WALK TEST; VENTRICULAR DIASTOLIC DYSFUNCTION; HEART-FAILURE; OUTCOMES; RECOGNITION; PREVALENCE; PROGNOSIS; GRADIENT; DISEASE; MARKER;
D O I
10.1111/resp.13067
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background and objective: Systemic sclerosis (SSc) is a complex autoimmune disease commonly associated with pulmonary hypertension (PH). When associated with elevated pulmonary artery wedge pressure (PAWP), pulmonary artery pressure (PAP) is either inproportion (post-capillary PH) or higher than expected (combined PH) relative to the increased PAWP. Methods: Patients from the PHAROS registry (a prospective observational cohort of SSc-PH patients) who had mean PAP >= 25 and PAWP > 15 on right heart catheterization were stratified based on diastolic pressure gradient (DPG). Kaplan-Meier analysis was performed to compare survival and PH-related hospitalization. Baseline factors were compared between patients dying and those who survived using Cox regression analysis. Results: A total of 59 patients were included, of whom 21 (36%) patients were classified as combined PH and 38 (64%) had post-capillary PH. No baseline characteristics were significantly different between the two groups. There were no differences in survival or PHrelated hospitalization between the groups. The only baseline factor independently associated with death was lower 6-min walk distance (6MWD) (hazard ratio (HR): 1.33 per 25 m decrease, 95% CI: 1.11-1.59, P = 0.002). PH-specific medications were started during follow-up in significantly more patients in the combined PH group compared with the post-capillary group (86% vs 50%, P = 0.01). Conclusion: Outcomes were similar between SSc patients with post-capillary PH and combined pre- and post-capillary PH. 6MWD at baseline can predict risk for death in SSc patients with PH and an elevated PAWP. More patients with combined PH were started on PH-specific medications, and the clinical benefit of treating this subgroup specifically in SSc patients needs further exploration.
引用
收藏
页码:1386 / 1392
页数:7
相关论文
共 50 条
  • [1] Hospital readmission in systemic sclerosis associated pulmonary hypertension: Results from the PHAROS registry
    Showalter, Kimberly
    Pinheiro, Laura C.
    Jannat-Khah, Deanna
    Sobol, Irina
    Szymonifka, Jackie
    Finik, Jackie
    Steen, Virginia D.
    Gordon, Jessica K.
    RHEUMATOLOGY, 2022, 61 (04) : 1510 - 1517
  • [2] Screening of pulmonary hypertension in a Spanish cohort of patients with systemic sclerosis
    Garcia Hernandez, Francisco Jose
    Castillo Palma, Maria Jesus
    Montero Mateos, Enrique
    Gonzalez Leon, Rocio
    Lopez Haldon, Jose Eduardo
    Sanchez Roman, Julio
    MEDICINA CLINICA, 2016, 146 (01): : 1 - 7
  • [3] Clinical and laboratory characteristics of systemic sclerosis patients with pulmonary arterial hypertension in China
    Huang, J.
    Li, M.
    Tian, Z.
    Hsieh, E.
    Wang, Q.
    Liu, Y.
    Xu, D.
    Hou, Y.
    Zhao, J.
    Guo, X.
    Lai, J.
    Hu, C.
    Song, N.
    Sun, Q.
    Zhang, F.
    Zhao, Y.
    Zeng, X.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (06) : S115 - S121
  • [4] Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry
    Hinchcliff, Monique
    Khanna, Saira
    Hsu, Vivien M.
    Lee, Jungwha
    Almagor, Orit
    Chang, Rowland W.
    Steen, Virginia
    Chung, Lorinda
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 45 (03) : 309 - 314
  • [5] Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry
    Hsu, Vivien M.
    Chung, Lorinda
    Hummers, Laura K.
    Shah, Ami
    Simms, Robert
    Bolster, Marcy
    Hant, Faye N.
    Silver, Richard M.
    Fischer, Aryeh
    Hinchcliff, Monique E.
    Varga, John
    Goldberg, Avram Z.
    Derk, Chris T.
    Schiopu, Elena
    Khanna, Dinesh
    Shapiro, Lee S.
    Domsic, Robyn T.
    Medsger, Thomas
    Mayes, Maureen D.
    Furst, Daniel
    Csuka, Mary Ellen
    Molitor, Jerry A.
    Saketkoo, Lesley Ann
    Salazar, Christian R.
    Steen, Virginia D.
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (02) : 176 - 183
  • [6] Prognostic significance of pericardial effusion in systemic sclerosis-associated pulmonary hypertension: analysis from the PHAROS Registry
    Luo, Yiming
    Gordon, Jessica K.
    Xu, Jiehui
    Kolstad, Kathleen D.
    Chung, Lorinda
    Steen, Virginia D.
    Bernstein, Elana J.
    RHEUMATOLOGY, 2023, : 1251 - 1258
  • [7] Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort
    Lammi, Matthew R.
    Saketkoo, Lesley Ann
    Gordon, Jessica K.
    Steen, Virginia D.
    PULMONARY CIRCULATION, 2018, 8 (02)
  • [8] SURVIVAL OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION, ASSOCIATED WITH SYSTEMIC SCLEROSIS
    Volkov, A. V.
    Martynyuk, T. V.
    Yudkina, N. N.
    Danilov, N. M.
    Glukhova, S. I. .
    Guseva, N. G.
    Chazova, I. E.
    Nasonova, V. A.
    TERAPEVTICHESKII ARKHIV, 2012, 84 (05) : 24 - 28
  • [9] Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort
    Shirai, Yuichiro
    Yasuoka, Hidekata
    Okano, Yutaka
    Takeuchi, Tsutomu
    Satoh, Toru
    Kuwana, Masataka
    RHEUMATOLOGY, 2012, 51 (10) : 1846 - 1854
  • [10] Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry
    Chung, L.
    Fairchild, R. M.
    Furst, D. E.
    Li, S.
    Alkassab, F.
    Bolster, M. B.
    Csuka, M. E.
    Derk, C. T.
    Domsic, R. T.
    Fischer, A.
    Frech, T. M.
    Gomberg-Maitland, M.
    Gordon, J. K.
    Hinchcliff, M.
    Hsu, V.
    Hummers, L. K.
    Khanna, D.
    Medsger, T. A., Jr.
    Molitor, J. A.
    Preston, I. R.
    Schiopu, E.
    Shapiro, L.
    Hant, F.
    Silver, R.
    Simms, R.
    Varga, J.
    Steen, V. D.
    Zamanian, R. T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (04) : S106 - S113